Market Overview

UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk

Related MYGN
Myriad myPath Melanoma Test Reduced Indeterminate Cases By 76% And Changed Treatment In 35 % Of Cases
Myriad Publishes myRisk Hereditary Cancer Study In Cancer

In a report published Friday, SunTrust Robinson Humphrey analyst Amit Hazan initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Reduce rating and $17.00 price target.

In the report, SunTrust Robinson Humphrey noted, “Our due diligence leads us to believe that the most imminent threat from new competitors for BRACAnalysis is not market share loss, but pricing pressures. We believe private insurer re-evaluation is currently ongoing on a broad scale and could realistically drive the price down by as much as 50% over the next two years. The Street's sales growth expectations for both FY14 and FY15 imply little to no pricing pressure, and we view that as a significant risk. The recent CMS reduction of COLARIS reimbursement by 46% is a good proxy here.”

Myriad Genetics closed on Thursday at $24.57.

Latest Ratings for MYGN

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral
May 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Amit Hazan SunTrust Robinson HumphreyAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters